Libertas Academica: August 2009

Monday, August 31, 2009

Interview with Translational Oncogenomics editorial board member Dr James Connor

This interview is with Translational Oncogenomics editorial board member Dr James Connor. Translational Oncogenomics is an open access journal published by Libertas Academica.

Editor in Chief Dr Michael Spinella has recently issued a call for papers.

What is the primary focus of your work and main areas of expertise?

The primary focus of our work is on iron metabolism in the brain. This includes genetic variations that may impact iron availability to the brain, mechanisms of brain iron transport, iron utilization by cancer cells, impact of gene allelic variants on brain tumors. The latter area in particular is not specific to brain tumors. Much of our work has relevance to a number of neurological disorders such as Alzheimer's Disease, Parkinson's Disease, Restless Legs Syndrome and Multiple Sclerosis.

What are the most exciting and cutting-edge developments in your area?

Currently we are particularly excited about our work focusing on the association of HFE gene variants and neurodegenerative diseases. In addition we have discovered an H-ferritin receptor that appears to be a selective uptake mechanism for iron delivery to oligodendrocytes.

Who are your main formal and informal collaborators and/or networks? Please describe your work with them.

We have a number of collaborative activities. These include a NIH funded program project with colleagues at Johns Hopkins on Restless Legs Syndrome and a program project with colleagues at the University of Michigan, Minnesota and UC Davis on the effects of iron deficiency on the developing brain across species including humans.

How did you come to be working in your research area?

We began over 25 years ago by looking for the expression of transferrin, the iron mobilization protein in the brain. Much of our early success and the development of our research program stemmed from the interest in oxidative stress in neurodegenerative diseases. Iron is the most potent pro-oxidant in biological systems.

What articles and/or books have you published recently?

The Impact of Host Iron Homeostasis on Disease (A Ghio and J. Connor, eds) Biochimica et Biophysica Acta 1790, 2009.
Connor JR, Wang XS, Allen RP, Beard JL, Wiesinger JA, Felt BT, Earley CJ: Altered dopaminergic profile in the putamen and substantia nigra in restless legs syndrome. In press, Brain.
Todorich B, Zhang X, Slagle-Webb B, Seaman WE, Connor JR: Tim-2 is the receptor for H-ferritin and oligodendrocytes. Journal of Neurochemistry 107:1495-1505, 2008.
Mitchell RM, Freeman WM, Randazzo WT, Stephens HE, Beard JL, Simmons Z, Connor JR. A CSF biomarker panel for identification of patients with Amyotrophic Lateral Sclerosis. Neurology 72:14-19, 2009.
Madhankumar AB, Slagle-Webb B, Wang X, Yang Q, Antonetti D, Miller P, Sheehan J, Connor JR: Efficacy of IL-13 receptor targeted liposomal doxorubicin in the intracranial brain tumor model. In press, Molecular Cancer Therapeutics, Jan, 2009.
Todorich B, Pasquini J, Garcia C, Paez P, Connor J: Oligodendrocytes and myelination: the role of iron. GLIA 57:467-478, 2009.

Further information about Dr Connor:

Contact Dr Connor

See the latest call for papers for Translational Oncogenomics

Friday, August 28, 2009

Interview with Glycobiology Insights editorial board member Dr Alberto Passi

Dr Alberto Passi is a member of the editorial board of Glycobiology Insights. In this interview Dr Passi discusses his research, recently published articles and his views on open access publishing.

The Editor in Chief of Glycobiology Insights recently issued a call for papers.

What is the primary focus of your research?

I am interested in glycosaminoglycan metabolism and in particular I am working now on the UDP sugars synthesis in different human cell lines. We demonstrated that the UDP sugars availability regulates the GAG synthesis and the covalent modification of the enzymes involved in these processes are the critical key point for a fast response during metabolic changes in the cells. At the moment we are focused on hyaluronan metabolism as model in this context, in general the production of GAG is finely regulated and the alteration of GAG content is reported in several pathologies.

What are the most exciting developments arising from current research in your area?

I think that there are at least two main aspects which improved dramatically our knowledge, one is the use of transfection in order to modifying the enzymes expression and activity, the second is the fast growing field of mass spectrometry applied to glycobiogy which improved its sensitivity and gives to scientists new information of extraordinary importance starting from a very low amount of material.

The fine structural definition and the possibility to manipulate the glycostructure is in my opinion the most important development in the last years in our field.

Who are your main collaborators? Please describe your work with them.

My main collaborators are in Biomedical Engineering Department of the Cleveland Clinic Foundation in Cleveland, in Harvard, in Europe we collaborate with scientists from Ludwig Cancer Institute in Uppsala (Sweden), in Kuopio (Finland) and Muenster (Germany). Vince Hascall in Cleveland is my mentor in this field and we are part of a network of people working together exchanging ideas, projects, reagents and collaborators; in fact people of my lab travels several times a year around the world in order to use specific techniques and equipment. For instance we collaborate with Markku and Raja Tammi in Kuopio in order to learn how to use confocal microscopy in vivo, with Evi Heldin in Uppsala to learn how to purify protein from cell membranes, in Muenster in Martin Goette lab to approach the biochemistry of Golgi apparatus, and in Boston to learn some bioinformatics in Marco Ramoni's lab.

How did you come to be working in your research area?

As often for chance. When I was in Medical School in hematology unit I started a period of training in biochemistry before graduation. There I found interesting some aspects of mucopolysaccharidoses, diseases very rare and in Italy few labs were able to make a diagnosis. So started my story from clinic to research in matrix biology area. The specific interest in GAG metabolism and hyaluronan in particular started in Hascall's lab in Cleveland during a two years of sabbatical from my university.

What do you think about the development of open access publishing?

I think that the open access publishing is extremely interesting, in particular considering the increase of costs for scientific publications and even for reviewing processes. As scientist I consider the diffusion of the knowledge a primary requirement for scientific progress. The only critical point is the rigorous review process in order to guarantee the scientific level of the publications. This aspect has to be the principal point of the open access journal. I am in the board of a couple of open access journals and I have found several excellent contributions even from labs operating in countries with poor economy. I think that an open access journal may represent a way to publish worlwide good results with low costs and this is critical for scientists working in poor countries.

What articles and/or books have you published recently?

Recently I published:

Vigetti D, et al. The effects of 4-methylumbelliferone on hyaluronan synthesis, MMP2 activity, proliferation, and motility of human aortic smooth muscle cells. Glycobiology. 2009 May;19(5):537-46
Vigetti D, et al. Vascular pathology and the role of hyaluronan. Scientific World Journal. 2008 Nov 2;8:1116-8
Vigetti D et al. Hyaluronan-CD44-ERK1/2 regulate human aortic smooth muscle cell motility during aging. J Biol Chem. 2008 Feb 15;283(7):4448-58.16.
Viola M, et al. New electrophoretic and chromatographic techniques for analysis of heparin and heparan sulfate. Electrophoresis. 2008 Aug;29(15):3168-74.
Vigetti D et al. Chondroitin sulfates act as extracellular gating modifiers on voltage-dependent ion channels. Cell Physiol Biochem. 2008;22(1-4):137-46.

More information:

Contact Dr Passi

See latest call for papers for Glycobiology Insights

Thursday, August 27, 2009

Interview with Retrovirology: Research and Treatment author Dr Krishan K Pandey

Dr Krishan K Pandey is the author of HIV-1 Integrase Strand Transfer Inhibitors: Novel Insights into their Mechanism of Action, which was recently published in Retrovirology: Research and Treatment. In this interview Dr Pandey discusses his research, recently published articles and his views on open access publishing.

The Editor in Chief of Retrovirology: Research and Treatment recently issued a call for papers.

What is the primary focus of your research?

We utilize various biochemical and biophysical tools to investigate the mechanisms associated with retroviral integration. We are investigating the mode of action of integrase strand transfer inhibitors including Raltegravir and development of drug resistance in HIV-1.

What are the most exciting developments arising from current research in your area?

Recently, we identified the synaptic complex, a transient intermediate in the HIV-1 concerted integration pathway in vitro. In the synaptic complex, the two viral DNA ends are juxtaposed by integrase non-covalently. Upon binding a target DNA, the synaptic complex produces the strand transfer complex, the terminal nucleoprotein product in the concerted integration pathway. We resolve these complexes by native agarose gel electrophoresis. We also determined that most integrase strand transfer inhibitors prevent the conversion of synaptic complex to strand transfer complex by inhibiting the binding of target DNA to synaptic complex, possibly by modifying viral DNA binding.

Who are your main collaborators? Please describe your work with them.

We have been collaborating with Merck & Co over several years and have investigated integrase inhibitors developed by Merck. In 2007, Raltegravir produced by Merck, became the first integrase inhibitor approved by the FDA for treatment of HIV-1 infections.

How did you come to be working in your research area?

I work in the laboratory of Dr. Duane Grandgenett and currently hold a Faculty Research Associate position.

What do you think about the development of open access publishing?

Open access publishing is important for the scientific community because it delivers the most recent knowledge to a much broader audience.

What articles and/or books have you published recently?

Pandey KK, Sinha S, Grandgenett DP (2007). Transcriptional coactivator LEDGF/p75 modulates human immunodeficiency virus type 1 integrase-mediated concerted integration. J Virol 81(8): 3969-3979.
Pandey KK, Bera S, Zahm J, Vora A, Stillmock K, Hazuda D, Grandgenett DP (2007). Inhibition of human immunodeficiency virus type 1 concerted integration by strand transfer inhibitors which recognize a transient structural intermediate. J Virol 81(22): 12189-12199.
Zahm JA, Bera S, Pandey KK, Vora A, Stillmock K, Hazuda D, Grandgenett DP (2008). Mechanisms of human immunodeficiency virus type 1 concerted integration related to strand transfer inhibition and drug resistance. Antimicrob Agents Chemother 52(9): 3358-3368.
Grandgenett DP, Bera S, Pandey KK, Vora AC, Zahm J, Sinha S (2009). Biochemical and biophysical analyses of concerted (U5/U3) integration. Methods 47(4): 229-236.
Bera S, Pandey KK, Vora AC, Grandgenett DP (2009). Molecular interactions between HIV-1 integrase and the two viral DNA ends within the synaptic complex that mediates concerted integration. J Mol Biol 389(1): 183-198.

More information:

Contact Dr Pandey

See latest call for papers for Retrovirology: Research and Treatment

Interview with Genomics Insights author Dr Hang Fai Kwok

Dr Hang Fai Kwok is the author of DNA in Amphibian and Reptile Venom Permits Access to Genomes Without Specimen Sacrifice, which was recently published in Genomics Insights. In this interview Dr Kwok discusses his research, recently published articles and his views on open access publishing.

The Editor in Chief of Genomics Insights recently issued a call for papers.

What is the primary focus of your research?

Venom research for drug discovery.

What are the most exciting developments arising from current research in your area?

Developed a non-invasive manner that circumvents specimen sacrifice. From a single sample of amphibian skin secretion and reptile venom, robust and complementary proteome, transcriptome and genome data can be generated for applications in diverse scientific discipline.

Who are your main collaborators? Please describe your work with them.

Craig Ivanyi from the Arizona-Sonora Desert Museum in Arizona, USA. We worked together for the acqisition of venoms.

What do you think about the development of open access publishing?

It is very good and useful to having the open access publishing. The journal allows readers to freely access the latest advances in the field. It also allows free flow of scientific thought much more rapidly.

What articles and/or books have you published recently?

'A central role for venom in predation by Varanus komodoensis (Komodo Dragon) and the extinct giant Varanus (Megalania) priscus'

See latest call for papers for Genomics Insights

Interview with Clinical Medicine: Dermatology author Dr Basil Hantash

Dr Basil Hantash is the author of several papers which were recently published in Clinical Medicine: Dermatology. In this interview Dr Hantash discusses his research, recently published articles and his views on open access publishing.

What is the primary focus of your research?

Skin aging and regeneration/rejuvenation immune tolerance.

What are the most exciting developments arising from current research in your area?

We have unmasked a potential mechanism by which skin aging may be decelerated. We are currently investigating whether this mechanism can be triggered through EMR-based skin treatment.

How did you come to be working in your research area?

I trained as a postdoctoral scholar at Stanford University's Program for Regenerative Medicine, and became interested in skin aging through my medical specialization in dermatology.

What do you think about the development of open access publishing? What motivated you to publish in this journal?

I think this is a fantastic opportunity to disseminate research findings rapidly and openly.

What articles and/or books have you published recently?

Cosmeceutical Agents: A Comprehensive Review of the Literature
Nonablative Skin Tightening: A Review of the Literature

Wednesday, August 26, 2009

Interview with Evolutionary Bioinformatics editorial board member Dr Olivier Bastien

This interview is with Evolutionary Bioinformatics editorial board member Dr Olivier Bastien. Evolutionary Bioinformatics is an open access journal published by Libertas Academica.

Editor in Chief Dr Dennis Wall has recently issued a call for papers.

What is the primary focus of your work and main areas of expertise?

I began to work on the development of theoretical and numerical mathematical tools for the genome comparison. The main goal of these work was to applied to the study of the malaria genome, namely Plasmodium falciparum, and its evolution. Rapidly, I have extend my research area to the fundamentals and the theoretical basis of the genome comparison and the sequence comparison.

In addition to these topics, I work on applied dynamical systems to regulatory metabolism network and on the development of bioinformatics tools for new biological technologies like Chip-On-Chip. One way to summarize my work is to say that I'm working on application of the Information Theory on Biological Systems.

What are the most exciting and cutting-edge developments in your area?

I have developed a new model for understanding the origin of the form of the pairwise alignment scores distribution based on a new approach using both reliability theory and information theory. The development of a new set of tools called Genobrower and GenoChip for epigenetic studies is also an recent important which have contribute to important advances in the Toxoplasma gondii epigenetic research field.

Who are your main formal and informal collaborators and/or networks? Please describe your work with them.

I am affiliated with the Institut National de la Recherche Agronomique (INRA). My main collaborators include Dr. Mohamed-Ali Hakimi (INSERM, for all epigenetic works), Dr Nicolas Glade (Grenoble University, for Theoretical Biology) and Dr Sylvain Lespinats (CEA, for Theoretical Biology). Based on Grenoble (France), I have developped a strong collaboration within my laboratory (The Laboratoire de Physiologie Cellulaire Végétale) including Dr Eric Maréchal, Dr Maryse Block, Dr Gilles Curien and Dr Fabrice Rébeillé.

How did you come to be working in your research area?

I come to work in my research area with the observation that theoretical biologists were really wanted by Molecular Biology. It was a great wish of René Thom, the father of the catastrophe theory.

What do you think about the development of open access publishing? Have you published in an open access journal? What motivated you to do so?

I have published in many open access journals. I was first motivated because I think it is a great improvement for developing countries' scientists. Moreover, as said by Jean Hladik, knowledge is the only things that future generations can inherit without charge. It is a way to ensure the free diffusion of knowledge all over the world.

What articles and/or books have you published recently?

Glade, N., Ben-Amor, H. and Bastien, O. (2009): “Trail Systems as fault tolerant wires and their use in bio-processors”. Epigenomic Program Spring School, La Colle sur Loup, France.
Curien, G., Bastien, O., Robert-Genthon, M., Cornish-Bowden, A., Cardenas, M.L. and Dumas, R. (2009): “Understanding regulation of aspartate metabolism with a model based on measured kinetic parameters”. Mol. Sys. Biol. 5: 271.
Grando, D., Ortet, P., Jourbert, F., Maréchal, E. and Bastien, O. (2009): “TULIP software and web server: automatic classification of protein sequences based on pairwise comparisons and Z-value statistics”. Open Bioinformatics Journal. In Press.
Bougdour, A., Maubon, D., Baldacci, P., Ortet, P., Bastien, O., Bouillon, A., Barale, J.C., Pelloux, H., Menard, R. And Hakimi, M.A. (2009): “Drug-inhibition of HDAC3 and epigenetic control of differentiation in Apicimplexa parasites”. J. Exp. Med. In Press.
Sautel, C.F., Ortet, P., Saksouk, N., Kieffer, S., Garin, J., Bastien, O. and Hakimi, M.A. (2008): “The histone methylase KMTox interacts with 1 the redox-sensor peroxiredoxin-1 and targets genes involved in Toxoplasma gondii antioxidant defenses”. Mol. Micro. 71(1): 212-226.
Bastien, O. and Maréchal, E. (2008): “Evolution of biological sequences implies Extreme Value Distribution of type I for both global and local pairwise alignment score”. BMC Bioinformatics 9: 332.
Saidani, N., Grando, D., Valadie, H., Bastien, O. and Maréchal, E. (2008): “Potential and limits of in silico target discovery--Case study of the search for new antimalarial chemotherapeutic targets”. Infect., Genet. and Evol., In Press.
Bastien, O. (2008): “A simple derivation of the distribution of pairwise local protein sequence alignment scores”. Evolutionary Bioinformatics 4:41-45

Further information:

Chemogénomique comparative des plantes et des parasites apicomplexes

Send Dr Bastien an email

See the latest call for papers for Evolutionary Bioinformatics

Tuesday, August 25, 2009

Call for papers for Gene Regulation and Systems Biology from Dr James Willey

On behalf of the Editorial Board I invite you to submit your next article to Gene Regulation and Systems Biology, an open access electronic journal published by Libertas Academica. The journal specializes in providing wide and open access to high quality manuscripts reporting on regulation of genes and the proteins they encode and the relationship between gene regulation and the wider field of systems biology.

We accept original studies and thoughtful reviews, surveys, opinions, commentaries, techniques, and essays. All submitted articles will be considered and peer-reviewed.

We provide an efficient, constructive peer review of manuscripts, with an editorial decision in less than 2 weeks for 90% of the papers submitted. Since the journal is open access, dissemination of the work is rapid and is available to anyone with an internet connection, leading to wide exposure for your published article.

We look forward to receiving your manuscript.

What is the advantage to you of publishing in Gene Regulation and Systems Biology?

Full open access: everyone can read your article and you retain copyright in it
Publishing decision within 2 weeks of submission
Your paper will not be rejected due to lack of space and will be published immediately on acceptance
Prompt and fair peer review from two expert peer reviewers
Frequent updates on your paper’s status
Friendly responsive staff

What a previous author said:

In summary:

The advantages of a younger journal such as Gene Regulation and Systems Biology are numerous but in essence allow us a greater flexibility and responsiveness to authors and readers that older journals cannot match.

Next steps:

Visit the journal's home page (full open access to all articles)
Instructions for authors
Submit a manuscript now (fast 3-step submission process)
Send me an inquiry

Yours sincerely,
Dr James C. Willey

Editor-in-Chief
Gene Regulation and Systems Biology

See other news items for Gene Regulation and Systems Biology

Call for papers for Cancer Informatics from Dr James Willey

On behalf of the Editorial Board I invite you to submit your next article to Cancer Informatics, an open access electronic journal published by Libertas Academica. The journal specializes in providing wide and open access to high quality manuscripts reporting bioinformatic analysis of molecular genetic and/or clinical data pertaining to human cancer risk, prevention, outcome or treatment response.

We accept original studies and thoughtful reviews, surveys, opinions, commentaries, techniques, and essays. All submitted articles will be considered and peer-reviewed.

We provide an efficient, constructive peer review of manuscripts, with an editorial decision in less than 2 weeks for 90% of the papers submitted. Since the journal is open access, dissemination of the work is rapid and is available to anyone with an internet connection, leading to wide exposure for your published article.

We look forward to receiving your manuscript.

What is the advantage to you of publishing in Cancer Informatics?

Full open access: everyone can read your article and you retain copyright in it
Publishing decision within 2 weeks of submission
Your paper will not be rejected due to lack of space and will be published immediately on acceptance
Prompt and fair peer review from two expert peer reviewers
Frequent updates on your paper’s status
Friendly responsive staff

What a previous author said:

In summary:

The advantages of a younger journal such as Cancer Informatics are numerous but in essence allow us a greater flexibility and responsiveness to authors and readers that older journals cannot match.

Next steps:

Visit the journal's home page (full open access to all articles)
Instructions for authors
Submit a manuscript now (fast 3-step submission process)
Send me an inquiry

Yours sincerely,
Dr James C. Willey

Editor-in-Chief
Cancer Informatics

See other news items for Cancer Informatics

Interview with Biomarkers in Cancer editorial board member Dr Feng Jiang

This interview is with Biomarkers in Cancer editorial board member Dr Feng Jiang. Biomarkers in Cancer is a new open access journal recently launched by Libertas Academica. Editor in Chief Dr Barbara Guinn has recently issued a call for papers.

What is the primary focus of your research?

Identifying genes that contribute to cancer development and progression, and translating the resultant information and technologies into clinic for diagnosis and therapeutic interventions of tumors, particularly, lung cancer, which is the most lethal of all cancers.

What are the most exciting developments arising from current research in your area?

I have developed genomic biomarkers that can be detected in sputum for the early detection of lung cancer (Clin Cancer Res. 2007, Cancer 2008). The research was recently reported in AACR Breaking News and NBC News.

What articles and/or books have you published recently?

Katz RL, Zaidi TM, Fernandez RL, Zhang J, He W, Acosta C, Daniely M, Madi L, Vargas MA, Dong Q, Jiang XG (Jiang F), Caraway NP, Vaporciyan AA, Roth JA, Spitz MR. Automated detection of genetic abnormalities combined with cytology in sputum is a sensitive predictor of lung cancer. Mod. Pathol. 2008.
Qiu Q, Todd NW, Li R, Peng H, Liu Z, Yfantis HG, Katz RL, Stass SA, Jiang, F. Magnetic enrichment of bronchial epithelial cells from sputum for lung cancer diagnosis. Cancer. 2008. 6: 22-29.
Yendamuri S, Vaporciyan AA, Hofstetter W, Jiang F, Spitz MR, Swisher SG, Roth JA, and Katz RL. 3p22.1 and 10q22.3 Deletions Detected by Fluorescence In Situ Hybridization (FISH) A Potential New Tool for Early Detection of Non-small Cell Lung Cancer (NSCLC). J. Thorac. Oncol., 28. 2008.
Liu Z, Gartenhaus R, Tan M, Jiang F, Jiao X. Gene and Pathway Identification with Lp Penalized. Bayesian Logistic Regression. BMC Bioinformatics, 2008. 9:412.
Liu Z, Jiang, F. Gene Identification and survival prediction with supervised and unsupervised learning. Int. J. Data Mining and Bioinformatics, in press, 2009, Feb.
Qiu, Q., Todd, N.W., Liu Z, Stass, S.A., Jiang, F. ALDH1 Is a stem cell marker in lung cancer and predictor of poor clinical outcome. Mol. Cancer Res., 2009, March.
Zhao F, Zhao M, Auerbach A, D'Costa A, Rapoport A, Burger A, Sausville B, Stass S ,Jiang F, Sands A, Aguilera N Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy. Clin. Cancer Res., 2009, March.
Qiu, Q., Todd, N.W., Liu Z, Katz RL, Stass, S.A., Jiang, F. Combined Genetic Analysis of Sputum and Computed Tomography for Noninvasive Diagnosis of Non-Small-Cell Lung Cancer. Lung Cancer, 2009, January.
Xie Y., Todd, N.W., Liu Z, Katz RL, Stass, S.A., Jiang, F. Analysis of altered miRNA expression in sputum for diagnosis of non-small cell lung cancer. Lung Cancer, 2009. May 13.
Katz RL, Vargas MA, Jiang F, Caraway NP, Roth JA, Spitz MR, El-Zein R. Levels of genetically abnormal circulating cells in patients with lung cancer correlate with stage and genetic phenotype of tumor, recurrence and survival. Journal of Oncology. In press. 2009.
Liu Z, Tan M, and Jiang F. Regularized F-Measure Maximization for Feature Selection and Classification. Journal of Biomedicine and Biotechnology. 2009:61; 7946.

Further information about Dr Jiang:

Dr Jiang's faculty profile webpage

Send Dr Jiang an email

See the latest call for papers for Biomarkers in Cancer

Wednesday, August 19, 2009

Call for papers for Signal Transduction Insights from Dr Edgar Grinstein

On behalf of the Editorial Board and publisher it is my pleasure to cordially invite you to contribute your work to Signal Transduction Insights, an open access, peer-reviewed online journal published by Libertas Academica. We invite contributions covering all aspects of signal transduction in cells, from molecular and intracellular to inter cellular levels. The journal integrates research from various areas of biology and its applications in health.

We welcome high-quality research in the area of normal and abnormal signal transduction. This includes, but is not limited to, signaling systems involved in cell communication, cell growth and cell cycle control, cell differentiation, cellular senescence, cell death as well as relevant mechanisms controlling gene expression. Included is also research on signaling events related to functions of stem cells, carcinogenesis and cancerous stem cells. Of significant interest is research aimed at further understanding disease-related aberrations in signaling pathways and the fast-growing area of signal transduction therapy.

We welcome original research articles, reviews, commentaries, letters to the Editor, methodology articles, hypotheses and short reports. All submissions to Signal Transduction Insights are subject to prompt, objective and fair peer review undertaken by at least two leading experts in the field.

Signal Transduction Insights publishes articles accessible to all Internet users throughout the world, without any access boundaries. The journal is of greatest possible benefit both to researchers working in major institutions and to those where institutional libraries are unable to afford subscription fees for a full range of journals. Therefore, articles published in Signal Transduction Insights are immediately available to the scientific and clinical communities without delay upon publication and enjoy high visibility.

We are confident that Signal Transduction Insights will attract manuscripts of the highest quality.

What is the advantage to you of publishing in Signal Transduction Insights?

Full open access: everyone can read your article and you retain copyright in it
Publishing decision within 2 weeks of submission
Your paper will not be rejected due to lack of space and will be published immediately on acceptance
Prompt and fair peer review from two expert peer reviewers
Frequent updates on your paper’s status
Friendly responsive staff

What a previous author said:

In summary:

The advantages of a younger journal such as Signal Transduction Insights are numerous but in essence allow us a greater flexibility and responsiveness to authors and readers that older journals cannot match.

Next steps:

Visit the journal's home page (full open access to all articles)
Instructions for authors
Submit a manuscript now (fast 3-step submission process)
Send me an inquiry

Yours sincerely,
Dr Edgar Grinstein

Editor-in-Chief
Signal Transduction Insights

Call for papers for Clinical Medicine: Cardiology from Dr Martin LeWinter

I would like to encourage you to consider submitting your research papers to Clinical Medicine: Cardiology. We are interested in publishing papers covering a wide range of topics pertinent to clinical cardiology, ischemic, valvular, congenital and myocardial disease, arrhythmias and pacing, heart failure, imaging, epidemiology, decision analysis, primary and secondary prevention and associated translational research. We can assure you of a prompt, courteous and constructive review process and, as an on-line journal, a world-wide audience.

What is the advantage to you of publishing in Clinical Medicine: Cardiology?

Full open access: everyone can read your article and you retain copyright in it
Publishing decision within 2 weeks of submission
Your paper will not be rejected due to lack of space and will be published immediately on acceptance
Prompt and fair peer review from two expert peer reviewers
Frequent updates on your paper’s status
Friendly responsive staff

What a previous author said:

In summary:

The advantages of a younger journal such as Clinical Medicine: Cardiology are numerous but in essence allow us a greater flexibility and responsiveness to authors and readers that older journals cannot match.

Next steps:

Visit the journal's home page (full open access to all articles)
Instructions for authors
Submit a manuscript now (fast 3-step submission process)
Send me an inquiry

Yours sincerely,
Dr Martin LeWinter

Editor-in-Chief
Clinical Medicine: Cardiology

New journal Advances in Tumor Virology is launched

I'm pleased to announce the launch of Advances in Tumor Virology, an open access peer reviewed journal published by Libertas Academica. The journal is fortunate to have the support of an excellent Editor in Chief, Dr Frank J Jenkins, and an internationally respected editorial board.

See other news items for Advances in Tumor Virology

Interview with Advances in Tumor Virology Editor in Chief Dr Frank J Jenkins

This interview is with Dr Frank J Jenkins, Editor in Chief of Advances in Tumor Virology, a new electronic open access journal published by Libertas Academica.

Tom: What would you say is the primary focus of your research effort (and how do you refer to your 'sub-area')?

My primary research is on Kaposi’s sarcoma associated herpesvirus (KSHV), the causative agent of Kaposi’s sarcoma (KS), pleural effusion lymphomas and some forms of Castleman’s disease. Our research is focused on the epidemiology, immune responses and pathogenesis of this virus. My sub-area is molecular virology – studying viral gene functions.

Tom: What do you consider to be the most significant developments arising from research in your area?

In collaboration with Charles Rinaldo, we have led the field in identifying T cell responses to KSHV among infected individuals. We have also identified DC-SIGN as a cellular receptor for KSHV on several immune cells including dendritic cells and activated B cells.

Tom: What do you consider to be the most significant open questions and research challenges in your area?

It is unclear how KSHV transforms a cell leading to KS development. It is also unclear why men are at a significantly greater risk for development of KS than women.

Tom: Tell us about your collaborative research. Who else do you directly work with and what are the aims of your collaboration?

I have collaborated since 1995 with Charles Rinaldo at the University of Pittsburgh. Our research is focused on T cell responses to KSHV and studies on the cellular receptor for KSHV, DC-SIGN. I also collaborate with Clare Bunker at the University of Pittsburgh on the role of KSHV in increasing prostate cancer risk among men in the Caribbean island of Tobago.

Tom: Is balancing all these activities challenging? How do you deal with it and what tools do you find useful in doing so?

Keeping busy is part of the excitement. Like many of my colleagues, I work long hours; the key is good time management.

Tom: When did you decide to be primarily involved in the field that you are now in?

I have worked in the field of herpesviruses since 1979 when I entered graduate school. When KSHV was first reported in 1994, I jumped at the opportunity to work on a newly discovered tumor virus.

Tom: What resources do you find indispensible for your research work?

I think without a doubt, the internet is the most single indispensable tool used in research. The ability to search for investigators working in the same field and the ability to search literature databases is as important as any single research tool.

Tom: What do you think about the development of open access publishing and open access development? How has it changed your perspective on research or development practices?

Open access publishing allows an investigator’s research results to reach a much greater audience than publishing in a conventional journal. As I mentioned earlier, the utility of internet access allows almost anyone to read about your research if it’s published through an open access journal.

Tom: What books do you think should be required reading for researchers working in your area?

Individuals interested in working on herpesviruses must read current chapters/reviews on the field of herpesvirus. It is imperative that they have a clear understanding of the molecular biology of herpesviruses and then focus on the specifics of the individual virus they are studying.

Tom: What books are current on your reading list?

I am currently reading “Getting Things Done: The Art of Stress-Free Productivity” by David Allen. [Amazon.com]

Tom: Do you teach any courses? Is so, which ones?

I teach several courses:

Advanced Herpesviruses
Viral Pathogenesis
Laboratory Methods

Tom: Which historical research figures do you think have most influenced you in how you think about research? Why are they significant?

The strongest research influences in my life have been my research mentors. Drs Fred Rapp and Mary K. Howett at Penn State University and Dr. Bernard Roizman at the University of Chicago. Dr. Rapp taught me to always question dogma and when results do not agree with dogma, trust the results and keep digging. Dr. Howett taught me how to structure my research life; how to deal with students (she is my example when I am interacting with my own students). Dr. Roizman taught me how to view my research in terms of goals; how to plan appropriately and how to write research manuscripts.

Tom: Which meetings do you attend on a regular basis?

I attend meetings organised by the American Society for Virology.

Tom: If you could change something about how research in your area is conducted, used, perceived, or resourced, what would it be?

The conduct of research is driven by funding sources. As a result, what one focuses on is dependent in large part on what NIH and other funding agencies have deemed important. What is missing is the ability of a scientist to pursue their own ideas; free of outside influence. If you look through the history of science, many of the most important discoveries, turning points, etc were made as a result of independent research rather than the more common applied and focused research that occurs today.

My thanks to Dr Jenkins.

See other news items for Advances in Tumor Virology

Call for papers for Translational Oncogenomics from Dr Michael Spinella

On behalf of the Editorial board I invite you to submit your next article to Translational Oncogenomics, an open access electronic journal published by Libertas Academica. The journal specializes in providing wide and open access for high quality genomic scale data related to human cancer etiology, detection, prognosis and treatment. We accept original studies in basic and applied oncogenomics and thoughtful reviews, surveys, opinions, commentaries, techniques, and essays. All submitted articles will be considered and peer-reviewed.

We look forward to receiving your manuscript.

What is the advantage to you of publishing in Translational Oncogenomics?

Full open access: everyone can read your article and you retain copyright in it
Publishing decision within 2 weeks of submission
Your paper will not be rejected due to lack of space and will be published immediately on acceptance
Prompt and fair peer review from two expert peer reviewers
Frequent updates on your paper’s status
Friendly responsive staff

What a previous author said:

In summary:

The advantages of a younger journal such as Translational Oncogenomics are numerous but in essence allow us a greater flexibility and responsiveness to authors and readers that older journals cannot match.

Next steps:

Visit the journal's home page (full open access to all articles)
Instructions for authors
Submit a manuscript now (fast 3-step submission process)
Send me an inquiry

Yours sincerely,

Dr Michael Spinella

Editor-in-Chief

Translational Oncogenomics

See other news items for Translational Oncogenomics

Wednesday, August 12, 2009

Interview with Clinical Medicine: Reproductive Health author and Editor in Chief Dr Zeev Blumenfeld

Dr Zeev Blumenfeld is the Editor in Chief of Clinical Medicine: Reproductive Health and the author of several papers:

In this interview Dr Blumenfeld discusses his research, recently published articles and his views on open access publishing.

What is the primary focus of your research?

Preservation ovarian function and fertility in young women exposed to gonadotoxic chemotherapy.

What are the most exciting developments arising from current research in your area?

The improvement in cryopreservation of unfertilized ova and the validation of GnRH-a as an effective means of minimizing gonadal failure, by three prospective randomized studies and a meta-analysis.

How did you come to be working in your research area?

By the observation that premature ovarian failure after similar chemotherapy in prepubertal girls is only 8% versus 30-60% in women in the reproductive age.

What do you think about the development of open access publishing? Have you published in an open access journal? What motivated you to do so?

Yes, I think it is a great improvement for readers, especially scientists and physicians from developing countries, and young investigators, residents, and fellows all over the world.

What articles and/or books have you published recently?

Preservation of fertility in patients with cancer. Blumenfeld Z. N Engl J Med. 2009 Jun 18;360(25):2680-1.
The beneficial role of gonadotropin releasing hormone agonists on fertility preservation. Blumenfeld Z. Pediatr Blood Cancer. 2009 May 29.
GnRH-agonists in fertility preservation.Blumenfeld Z. Curr Opin Endocrinol Diabetes Obes. 2008 Dec;15(6):523-8. Review.
GnRH-analogues and oral contraceptives for fertility preservation in women during chemotherapy.Blumenfeld Z, von Wolff M. Hum Reprod Update. 2008 Nov-Dec;14(6):543-52. Epub 2008 Sep 29. Review.
How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries. Blumenfeld Z. Oncologist. 2007;12:1044-54. Review.
The neuroprotective effect of Activin A and B: implication for neurodegenerative diseases. Kupershmidt L, Amit T, Bar-Am O, Youdim MB, Blumenfeld Z. J Neurochem. 2007 Nov;103(3):962-71. Epub 2007 Aug 6.
Gonadotropin-releasing hormone agonist decreases chemotherapy-induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin lymphoma. Blumenfeld Z, Avivi I, Eckman A, Epelbaum R, Rowe JM, Dann EJ. Fertil Steril. 2008 Jan;89(1):166-73. Epub 2007 Jun 28.
Spontaneous pregnancy and normal delivery after repeated autologous bone marrow transplantation and GnRH agonist treatment. Blumenfeld Z, Benaroush M, Zuckerman T. Hum Reprod. 2007;22:2346. Epub 2007 Apr 23.
Preservation of Fertility and Ovarian Function and Minimizing. Chemotherapy Induced Gonadotoxicity in Young Women by GnRH. A. J.National Cancer Institute Monogr. 2005; 34:40-3.
Blumenfeld Z. Editorial—Recent Developments in Clinical Medicine: Reproductive Health. Clinical Medicine: Reproductive Health 2008:2 1-3. 14 Jul 2008
Blumenfeld Z. GnRH-agonists in fertility preservation. Current Opinion in Endocrinology, Diabetes, and Obesity. 2008 Dec; 15(6):523-8.
Blumenfeld Z, Abdallah W, Sela-Guttmann O, Brook OR. Triplet Gestation- Prevention, Risks, & Management Dilemmas. The Open Women’ Health Journal, 2008, 2, 11-21.
Blumenfeld Z, Abdallah W, Kaplan D, Nevo O. Endometrial thickness- a practical prospective marker for the risk of surgical intervention after RU486 induced abortion. Clinical Medicine: Reproductive Health. 2008:2; 25–30.
Blumenfeld Z. Premature ovarian failure: etiology and possible prevention. Expert Review of Endocrinology & Metabolism 2009; 4:173-181.

More information about Dr Blumenfeld:

My thanks to Dr Blumenfeld.

See the latest call for papers for Clinical Medicine: Reproductive Health

Thursday, August 6, 2009

Announcing our new widget

Today we launched our new widget. Now you can put a list of the latest articles published in your journal of choice on your webpage.

The widget automatically updates with new articles when they are published. Best of all, it is very simple to setup and use.

Just select the journal you want to see, then the number of articles (5, 10, 15 or 20) and click the button to generate the code you can then paste into any HTML web page.

The widget is still in beta and I would appreciate receiving feedback from users on improvements, bugs and any other thoughts. To provide feedback just send me an email.

Create a customised widget

Update (12/Aug): The widget also now covers subjects in addition to journals. Subjects covered: bioinformatics, biology, biomarkers, cancer, chemistry, drugs and therapeutics, genes, and medicine.

Get all new articles on bioinformatics, biology, biomarkers, cancer, chemistry, drugs and therapeutics, genes, and medicine on Twitter or RSS

Our new subject home pages enable you to be notified of all the new papers in specific subject areas.

You can also follow an entire subject area by RSS feed or Twitter:

Bioinformatics

Biology

Biomarkers

Cancer

Chemistry

Drugs and therapeutics

Genes

Medicine

See other news items for Twitter

See other news items for subject home pages

Monday, August 3, 2009

Call for papers for Bioinformatics and Biology Insights from Dr Erich Bornberg-Bauer

On behalf of the Editorial board I invite you to submit your next article to Bioinformatics and Biology Insights, an open access electronic journal published by Libertas Academica.

The main goal of the journal is to publish high quality papers, which foster the scope of bioinformatics for biological applications and increase the accessibility for biologists.

Accordingly, the journal not only publishes peer reviewed Original Research Reviews, Commentaries, Methodology articles and Short Reports. We are also happy to accommodate Meeting Reports, Turorials, Hyptheses and Short Letters.

What is the advantage to you of publishing in Bioinformatics and Biology Insights?

Full open access: everyone can read your article and you retain copyright in it
Publishing decision within 2 weeks of submission
Your paper will not be rejected due to lack of space and will be published immediately on acceptance
Prompt and fair peer review from two expert peer reviewers
Frequent updates on your paper’s status
Friendly responsive staff

Aims and scope:

Bioinformatics and Biology Insights is a journal that publishes papers in computational biology, particularly computational methods used in the analysis and annotation of structures..

What a previous author said:

In summary:

The advantages of a younger journal such as Bioinformatics and Biology Insights are numerous but in essence allow us a greater flexibility and responsiveness to authors and readers that older journals cannot match.

Next steps:

Visit the journal's home page (full open access to all articles)
Instructions for authors
Submit a manuscript now (fast 3-step submission process)
Send me an inquiry

Yours sincerely,
Dr Erich Bornberg-Bauer

Editor-in-Chief
Bioinformatics and Biology Insights

See other news items for Bioinformatics and Biology Insights

Interview with Bioinformatics and Biology Insights author Dr Wei Zhang

Dr Wei Zhang is the author of "The HapMap Resource is Providing New Insights into Ourselves and its Application to Pharmacogenomics" which was published in Bioinformatics and Biology Insights.

In this interview Dr Zhang discusses his research, collaborators, recently published articles and his views on open access publishing.

What is the primary focus of your research?

I am mostly interested in pharmacogenomics of anticancer drugs. We know that individuals may have different response to chemotherapeutic agents. Some respond well, but some may have serious side effects. Genetics is believed to play a critical role in drug response, which is likely to be a complex trait or phenotype. We, therefore, aim to identify genetic determinants that are responsible for drug response using cell-based,high throughput genome-wide approaches. Our gaol is personalized medicine through translational research.

What are the most exciting developments arising from current research in your area?

During the past few years, investigators have made significant progress in studying human genetic variation. Paricularly, the International HapMap Project provides a tremendous resource that has facilitated various studies including pharmcogenomic discovery. Currently, extensive genotypic (e.g., SNPs), Copy Number Variation and mRNA-level gene expression data are publicly available for the HapMap samples. Studies using the HapMap samples have begun to provide a lot of new insights into the natural variation of human beings. For example, our work as well as a couple of others' demonstrated significant gene expression differences between human populations. These results could potentially help explain the health-related differences between human populations (e.g., different drug response, different risks of common diseases).

Who are your main collaborators? Please describe your work with them.

I am affiliated with the Pharmaocogenetics of Anticancer Agents Research (PAAR) group based at the University of Chicago. The NIH-funded PAAR group is a member of the PGRN (Pharmacogenetics Research Network). My main collaborators include Dr. Mark Ratain (PAAR Chair), Dr. Eileen Dolan and Dr. Nancy Cox, who are Professors of Medicine at the University of Chicago.

What do you think about the development of open access publishing? Have you published in an open access journal? What motivated you to do so?

I strongly support open access publishing.I believe open access publishing can help authors reach as many readers as possible, therefore, it may increase the potential impact of the papers published.

What articles and/or books have you published recently?

Using the HapMap samples and our own Affymetrix exon array data, we published papers about population gene expression differences, genetic architecture of gene expression in humans, as well as gender differences in gene expression.

Zhang W, Duan S, Kistner EO, Bleibel WK, Huang RS, Clark TA, Chen TX, Schweitzer AC, Blume JE, Cox NJ and Dolan ME. Evaluation of genetic variation contributing to differences in gene expression between populations. The American Journal of Human Genetics. 2008; 82(3):631-640. PubMed ID: 18313023
Duan S, Huang RS, Zhang W, Bleibel WK, Roe CA, Clark TA, Chen TX, Schweitzer AC, Blume JE, Cox NJ and Dolan ME. Genetic architecture of transcript-level variation in humans. The American Journal of Human Genetics. 2008; 82(5):1101-1113. PubMed ID: 18439551
Zhang W, Huang RS, Duan S and Dolan ME. Gene set enrichment analyses revealed differences in gene expression patterns between males and females. In Silico Biology. 2009; 9(1): 0006.

More information about Dr Jiang:

My thanks to Dr Zhang.

See latest call for papers for Bioinformatics and Biology Insights

See other news items for Bioinformatics and Biology Insights

Call for papers for Journal of Brain Disease from Dr Bart Demaerschalk

On behalf of the Editorial Board it is my pleasure to invite you to submit your scholarly work to the Journal of Brain Disease published by Libertas Academica.

Journal of Brain Disease is an open access, peer-reviewed journal which covers all types of human brain diseases and disorders. Scientific work describing brain disease research, neurological education, and clinical neuroscience practice is welcomed. Adult and pediatric neurology, neurosurgery, neuroradiology, endovascular surgical neuroradiology, neuropsychiatry, neurorehabilitation, neuropharmacology, neurophysiology, and neuropathology specialties are represented. This open access journal facilitates rapid publication with immediate international exposure.

The Journal of Brain Disease offers you expedited intelligent reviews by international experts in the field, and is designed for rapid, free, and broad dissemination of knowledge to interested readers around the world. As the Editor-in-Chief, I can assure you of a fair, rigorous and quick review of all manuscripts submitted. I trust that you will agree that publishing in the Journal of Brain Disease is a great opportunity to disseminate your work to the international scientific and clinical neurological communities.

I hope to receive, review, and publish your manuscripts in the Journal of Brain Disease in the near future.

What is the advantage to you of publishing in Journal of Brain Disease?

Full open access: everyone can read your article and you retain copyright in it
Publishing decision within 2 weeks of submission
Your paper will not be rejected due to lack of space and will be published immediately on acceptance
Prompt and fair peer review from two expert peer reviewers
Frequent updates on your paper’s status
Friendly responsive staff

What a previous author said:

In summary:

The advantages of a younger journal such as Journal of Brain Disease are numerous but in essence allow us a greater flexibility and responsiveness to authors and readers that older journals cannot match.

Next steps:

Visit the journal's home page (full open access to all articles)
Instructions for authors
Submit a manuscript now (fast 3-step submission process)
Send me an inquiry

Yours sincerely,
Dr Bart Demaerschalk

Editor-in-Chief
Journal of Brain Disease

Call for papers for Integrative Medicine Insights from Dr Steve Gurgevich

You are invited to share your research findings, clinical techniques, and clinical cases that will enlighten your colleagues about integrative medicine. Because integrative medicine is inclusive, the range of topics possible for this journal is wide and expands across many fields of clinical application and study. I invite papers with rigorous research methods that can be easily replicated and withstand critical scrutiny just as much as I welcome papers that shed insight on techniques and applications that beg for future research.

For example, if your travels in the world led you to discover a culture with a unique manner of treating a medical condition, I would invite you to present a paper about it which facilitates an intellectual discussion. Or, you may want to share your ideas for future research on an integrative approach. The integrative medicine horizon is wide and open. I warmly encourage you to submit a thoughtful paper on your research, case studies, creative techniques and methods to Integrative Medicine Insights.

What is the advantage to you of publishing in Integrative Medicine Insights?

Full open access: everyone can read your article and you retain copyright in it
Publishing decision within 2 weeks of submission
Your paper will not be rejected due to lack of space and will be published immediately on acceptance
Prompt and fair peer review from two expert peer reviewers
Frequent updates on your paper’s status
Friendly responsive staff

What a previous author said:

In summary:

The advantages of a younger journal such as Integrative Medicine Insights are numerous but in essence allow us a greater flexibility and responsiveness to authors and readers that older journals cannot match.

Next steps:

Visit the journal's home page (full open access to all articles)
Instructions for authors
Submit a manuscript now (fast 3-step submission process)
Send me an inquiry

Yours sincerely,
Dr Steve Gurgevich

Editor-in-Chief
Integrative Medicine Insights

See other news items for Integrative Medicine Insights

Call for papers for Immunology and Immunogenetic Insights from Dr Darren Flower

Academic publishing is changing and so too is Immunology. Immunology and Immunogenetic Insights, a peer-reviewed, open access journal published by Libertas Academica brings these two rapidly changing endeavours together.

Immunology and Immunogenetic Insights seeks to cover all aspects of the immune system in health and disease from immunological through evolutionary immunology to cutting edge technologies, such as immunoinformatics and systems biology, embracing the whole of translational medicine and the quests for immunotherapies and vaccines. Thus, on behalf of myself, the Editorial Board, and the publisher, I invite you to contribute your next ground-breaking work to Immunology and Immunogenetic Insights.

What is the advantage to you of publishing in Immunology and Immunogenetic Insights?

Full open access: everyone can read your article and you retain copyright in it
Publishing decision within 2 weeks of submission
Your paper will not be rejected due to lack of space and will be published immediately on acceptance
Prompt and fair peer review from two expert peer reviewers
Frequent updates on your paper’s status
Friendly responsive staff

What a previous author said:

In summary:

The advantages of a younger journal such as Immunology and Immunogenetic Insights are numerous but in essence allow us a greater flexibility and responsiveness to authors and readers that older journals cannot match.

Next steps:

Visit the journal's home page (full open access to all articles)
Instructions for authors
Submit a manuscript now (fast 3-step submission process)
Send me an inquiry

Yours sincerely,
Dr Darren Flower

Editor-in-Chief
Immunology and Immunogenetic Insights

See other news items for Immunology and Immunogenetic Insights

Call for papers for Human Parasitic Diseases from Dr Ashley Croft

Dear colleagues,

This is a call for papers for Human Parasitic Diseases – a recently-established, peer-reviewed open access journal published by Libertas Academica. This important and exciting new has already attracted manuscripts of very high scientific quality. This is because Human Parasitic Diseases offers, and continues to offer, rigorous, fair and prompt standards of peer review. My policy as Editor-in-Chief is that anyone can contribute, and not only those in major institutions.

Open access means that all articles are freely available to all, worldwide, and at no cost to the reader. All articles published in Human Parasitic Diseases become available immediately to researchers worldwide, through electronic databases. Authors however retain copyright of their work. The advantages of open-access publication are ineluctable. I urge you to submit your article or articles now.

What is the advantage to you of publishing in Human Parasitic Diseases?

Full open access: everyone can read your article and you retain copyright in it
Publishing decision within 2 weeks of submission
Your paper will not be rejected due to lack of space and will be published immediately on acceptance
Prompt and fair peer review from two expert peer reviewers
Frequent updates on your paper’s status
Friendly responsive staff

Aims and scope:

Human Parasitic Diseases is a journal that publishes papers on parasitic diseases in humans.

What a previous author said:

In summary:

The advantages of a younger journal such as Human Parasitic Diseases are numerous but in essence allow us a greater flexibility and responsiveness to authors and readers that older journals cannot match.

Next steps:

Visit the journal's home page (full open access to all articles)
Instructions for authors
Submit a manuscript now (fast 3-step submission process)
Send me an inquiry

Yours sincerely,
Dr Ashley Croft

Editor-in-Chief
Human Parasitic Diseases

See other news items for Human Parasitic Diseases

Call for papers for Cell Biology Insights from Dr Jianping Xu

Dear Colleague,

We would like to communicate to you that we are currently accepting manuscripts in all areas of cell biology. The following types of papers are considered for publication in Cell Biology Insights: original articles in basic and applied cell biology research and critical reviews, surveys, opinions, commentaries, techniques, and essays. All submitted articles will be considered and peer-reviewed.

We look forward to receiving your manuscript.

What is the advantage to you of publishing in Cell Biology Insights?

Full open access: everyone can read your article and you retain copyright in it
Publishing decision within 2 weeks of submission
Your paper will not be rejected due to lack of space and will be published immediately on acceptance
Prompt and fair peer review from two expert peer reviewers
Frequent updates on your paper’s status
Friendly responsive staff

Aims and scope:

Cell Biology Insights is a journal that publishes papers in covers all aspects of microscopic and molecular cell biology.

What a previous author said:

In summary:

The advantages of a younger journal such as Cell Biology Insights are numerous but in essence allow us a greater flexibility and responsiveness to authors and readers that older journals cannot match.

Next steps: